Researchers used computational and structure-based design to develop compound I, a preclinical candidate for HIV therapy; compound I, a non-nucleoside reverse transcriptase inhibitor, exhibited synergistic properties with existing HIV-1 drugs and clinical candidates at the cellular level as well as suppressed viral loads and prevented human CD4+ T-cell loss in HIV-1-infected humanized mice, and a long-acting version of compound I sustained plasma drug concentrations and effectiveness for approximately 3 weeks in mice, suggesting that the compound might have a role in pre-exposure treatments.
###
Article #17-17932: "From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection," by Shalley Kudalkar et al.
MEDIA CONTACT: William Jorgensen, Yale University School of Medicine, New Haven, CT; tel: 860-767-8032; e-mail: < william.jorgensen@yale.edu >; Karen Anderson, Yale University School of Medicine, New Haven, CT; tel: 203-988-3535; e-mail: < karen.anderson@yale.edu >
Proceedings of the National Academy of Sciences